Drug Profile
T3D 959
Alternative Names: DB-959; DB-959Na; T3D-959Latest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer DARA BioSciences; T3D Therapeutics
- Class Acetates; Antidementias; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Indenes; Insulin sensitisers; Oxazoles; Small molecules; Sodium compounds
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Phase I Huntington's disease; Non-alcoholic fatty liver disease
- Discontinued Dyslipidaemias; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 03 Nov 2023 Efficacy, adverse events data and pharmacodynamics data from the phase II PIONEER trial in Alzheimer's disease released by T3D Therapeutics
- 03 Nov 2023 T3D Therapeutics plans a phase IIb/III trial for mild to moderate Alzheimer's disease
- 03 Oct 2023 Discontinued - Phase-I for Non-alcoholic steatohepatitis in USA (PO) (T3D Therapeutics pipeline, October 2023)